Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216729 | 0.88 | ACHE (0.48) | ACHEMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7217023 | 0.87 | ACHE (0.49) | ACHEMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7216927 | 0.87 | KDM4E (0.49) | ACHEMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7216865 | 0.74 | ACHE (0.43) | ACHEMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7220974 | 0.73 | DPP4 (0.38) | MAPK14MAPK13MAPK12MAPK11SLC6A3 | |
| SCHEMBL7221098 | 0.70 | TAAR1 (0.39) | MAPK14MAPK13MAPK12MAPK11SLC6A3 | |
| SCHEMBL7216749 | 0.70 | LOXL2 (0.38) | MAPK14SLC6A3ALOX5 | |
| SCHEMBL7220444 | 0.69 | PRCP (0.41) | SLC6A3 | |
| SCHEMBL7214446 | 0.68 | NPC1 (0.38) | KDM4ESLC6A3 | |
| SCHEMBL3344245 | 0.68 | ACHE (0.61) | ACHEKDM4ESLC6A3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |